PFE · 10-Q · 2026Q2 · Full report

Guidance / Outlook

PFIZER INC · 2026-08-04 · Importance 47 · Surprise 42

Pfizer expects leverage to remain around current levels, or modestly higher, through the next several years because of anticipated unfavorable effects from patent-based and regulatory exclusivity expiries. Management intends to continue deleveraging over time while maintaining reinvestment and dividend-growth priorities. Share repurchases are contemplated only after further balance-sheet deleveraging, and Pfizer had $3.3 billion of remaining repurchase authorization as of June 28, 2026, with no repurchases during the first six months.

Key facts

• Pfizer's forward-looking statements include expectations that leverage will de-lever over time in a prudent manner to maintain a balanced capital allocation strategy. source
• Forward-looking information in the Form 10-Q includes statements about anticipated operating and financial performance, including financial guidance and projections, and the anticipated costs, savings and potential benefits from the enterprise-wide Realigning Our Cost Base Program and Manufacturing Optimization Program. source